Oncology drug costs overall, and immunotherapy costs specifically, drove Medicare spending increases for outpatient end-of-life cancer care, according to research in International Journal of Radiation Oncology, Biology, Physics.Expanding use of biosimilars may be an effective approach to moderate cancer drug costs, researchers concluded.
Immunotherapy Costs Drive Increase in Medicare Spending for Outpatient Cancer Care at the End of Life itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.
A new study finds that recent increases in Medicare spending on outpatient cancer care at the end of patients' lives were driven almost entirely by a type of treatment given to fewer than 1 in 5 patients.
CMS Proposed 22% Cut to Radiation Oncology Is Tone Deaf medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.